Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Galli L, Chiuri VE, Di Lorenzo G, Pisconti S, Rossetti S, Sirotova Z, Muto A, Petrioli R, De Tursi M, Sbrana A, Francolini G, Ardizzoia A, Scavelli C, Satta F, Quadrini S, Airoldi M, D'Aniello C, Bonetti A, Conforti S, Aieta M, Beccaglia P, Maestri A, Fratino L. Galli L, et al. Among authors: d aniello c. Tumori. 2023 Apr;109(2):224-232. doi: 10.1177/03008916221079662. Epub 2022 Apr 9. Tumori. 2023. PMID: 35400269 Free PMC article.
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G, DʼAniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Di Lorenzo G, et al. Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc. Anticancer Drugs. 2013. PMID: 23044721
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. Eur Urol. 2015. PMID: 25457020
Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.
Perri F, Pisconti S, Conson M, Pacelli R, Della Vittoria Scarpati G, Gnoni A, D'Aniello C, Cavaliere C, Licchetta A, Cella L, Giuliano M, Schiavone C, Falivene S, Di Lorenzo G, Buonerba C, Ravo V, Muto P. Perri F, et al. Onco Targets Ther. 2015 Jun 8;8:1345-9. doi: 10.2147/OTT.S75232. eCollection 2015. Onco Targets Ther. 2015. PMID: 26089683 Free PMC article.
From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.
Facchini G, Della Pepa C, Cavaliere C, Cecere SC, Di Napoli M, D'Aniello C, Crispo A, Iovane G, Maiolino P, Tramontano T, Piscitelli R, Pisconti S, Montella M, Berretta M, Sorrentino D, Perdonà S, Pignata S. Facchini G, et al. Front Pharmacol. 2016 May 3;7:110. doi: 10.3389/fphar.2016.00110. eCollection 2016. Front Pharmacol. 2016. PMID: 27199753 Free PMC article.
146 results